Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15575103 | 0.87 | ALDH1A1 (0.75) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL17479215 | 0.86 | ALDH1A1 (0.78) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL925723 | 0.86 | ALDH1A1 (0.78) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1710961 | 0.84 | ALDH1A1 (1.00) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL15899792 | 0.84 | ALDH1A1 (0.76) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL26144898 | 0.84 | LMNA (0.71) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL28310369 | 0.83 | ALDH1A1 (0.70) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL15575811 | 0.83 | HTR2B (0.60) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL17479352 | 0.82 | ALDH1A1 (0.76) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL17479214 | 0.82 | ALDH1A1 (0.76) | ALDH1A1LMNAKMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113444063-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113321632-A | Sulfamoyl-arylamides and their use as medicaments for the treatment of hepatitis B | 爱尔兰詹森科学公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-2890375-B1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-07-28 | — | — | EP | disclosed |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-05-04 | — | — | US | disclosed |
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-01-28 | — | — | US | disclosed |
| US-20200255373-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-08-13 | — | — | US | disclosed |
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-06-09 | — | — | US | disclosed |
| US-20180127361-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-10 | — | — | US | disclosed |
| US-20150274653-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| US-20150266890-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-24 | — | — | US | disclosed |
| EP-2890375-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2015-07-08 | — | — | EP | disclosed |
| EP-2890688-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014033170-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014033176-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | ALDH1A1 2263/4885LMNA 2178/4885KMT2A 543/4885 |
| US-20150274653-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | ALDH1A1 2263/4885LMNA 2178/4885KMT2A 543/4885 |
| US-20180127361-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | ALDH1A1 2263/4885LMNA 2178/4885KMT2A 543/4885 |
| US-20150266890-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | ALDH1A1 2263/4885LMNA 2178/4885KMT2A 543/4885 |
| US-20200255373-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | ALDH1A1 2263/4885LMNA 2178/4885KMT2A 543/4885 |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | ALDH1A1 2263/4885LMNA 2178/4885KMT2A 543/4885 |
| US-20210024462-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | ALDH1A1 2263/4885LMNA 2178/4885KMT2A 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.